NASDAQ:ATRA - Atara Biotherapeutics Stock Price, Forecast & News

$15.03

-0.96 (-6.00 %)

(As of 01/19/2020 04:00 PM ET)

Add

Compare

Today's Range

$15.03

Now: $15.03▼

$16.15

50-Day Range

$13.49

MA: $15.64▼

$17.79

52-Week Range

$10.38

Now: $15.03▼

$41.97

Volume611,689 shs

Average Volume713,854 shs

Market Capitalization$813.87 million

P/E RatioN/A

Dividend YieldN/A

Beta2.07

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ATRA

Previous Symbol

CUSIPN/A

CIK1604464

Webhttp://www.atarabio.com/

Phone650-278-8930

Debt

Debt-to-Equity Ratio0.05

Current Ratio9.56

Quick Ratio9.56

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$7.42 per share

Price / Book2.03

Profitability

EPS (Most Recent Fiscal Year)($5.27)

Net Income$-230,700,000.00

Net MarginsN/A

Return on Equity-99.70%

Return on Assets-86.31%

Miscellaneous

Employees321

Outstanding Shares54,150,000

Market Cap$813.87 million

Next Earnings Date2/25/2020 (Estimated)

OptionableOptionable

Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

(Ad)

Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics Inc (NASDAQ:ATRA) posted its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.31) EPS for the quarter, topping the consensus estimate of ($1.40) by $0.09. View Atara Biotherapeutics' Earnings History.

When is Atara Biotherapeutics' next earnings date?

Atara Biotherapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Atara Biotherapeutics.

What price target have analysts set for ATRA?

11 Wall Street analysts have issued twelve-month price objectives for Atara Biotherapeutics' stock. Their forecasts range from $9.00 to $70.00. On average, they expect Atara Biotherapeutics' stock price to reach $29.88 in the next twelve months. This suggests a possible upside of 98.8% from the stock's current price. View Analyst Price Targets for Atara Biotherapeutics.

What is the consensus analysts' recommendation for Atara Biotherapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atara Biotherapeutics.

What are Wall Street analysts saying about Atara Biotherapeutics stock?

Here are some recent quotes from research analysts about Atara Biotherapeutics stock:

1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (1/10/2020)
2. William Blair analysts commented, "We view the results as very promising given the high efficacy and very favorable safety profile, with no evidence of on-target, off-tumor toxicity of the CAR-T therapy . Given the strong expression of mesothelin across several tumor types, including mesothelioma (90%-plus), lung adenocarcinoma (60%-plus), triple negative breast cancer (TNBC, 35%), and pancreatic cancer (80%), the opportunity for a mesothelin- CAR-T therapy with a strong safety profile is significant." (4/1/2019)
3. Mizuho analysts commented, "We note that this is not the first time the company has put an ATM in place." (2/26/2019)

Has Atara Biotherapeutics been receiving favorable news coverage?

News stories about ATRA stock have trended positive on Sunday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Atara Biotherapeutics earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Atara Biotherapeutics.

Are investors shorting Atara Biotherapeutics?

Atara Biotherapeutics saw a decrease in short interest during the month of December. As of December 13th, there was short interest totalling 9,570,000 shares, a decrease of 8.3% from the November 28th total of 10,440,000 shares. Based on an average daily trading volume, of 657,200 shares, the days-to-cover ratio is currently 14.6 days. Currently, 19.9% of the company's shares are short sold. View Atara Biotherapeutics' Current Options Chain.

Who are some of Atara Biotherapeutics' key competitors?

Some companies that are related to Atara Biotherapeutics include Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Cortexyme (CRTX), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX) and Orchard Therapeutics (ORTX).

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include Crispr Therapeutics (CRSP), Micron Technology (MU), Editas Medicine (EDIT), AbbVie (ABBV), Exelixis (EXEL), Nektar Therapeutics (NKTR), Portola Pharmaceuticals (PTLA), Alibaba Group (BABA), Heron Therapeutics (HRTX) and Progenics Pharmaceuticals (PGNX).

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the folowing people:

Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 48)
Mr. Utpal Koppikar, Chief Financial Officer (Age 49)
Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 49)
Ms. Mina Kim, Sr. VP of Corp. Strategy, Gen. Counsel & Sec. (Age 45)
Dr. Dietmar P. Berger M.D., Ph.D., Global Head of R&D (Age 56)

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.78%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Eric Dobmeier, Heather D Turner, Isaac E Ciechanover, Joe Newell, Joel S Marcus, John Mcgrath, Matthew K Fust, Mitchall G Clark and Utpal Koppikar. View Institutional Ownership Trends for Atara Biotherapeutics.

Which major investors are buying Atara Biotherapeutics stock?

ATRA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have bought Atara Biotherapeutics stock in the last two years include Eric Dobmeier and Utpal Koppikar. View Insider Buying and Selling for Atara Biotherapeutics.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $15.03.

How big of a company is Atara Biotherapeutics?

Atara Biotherapeutics has a market capitalization of $813.87 million. The biotechnology company earns $-230,700,000.00 in net income (profit) each year or ($5.27) on an earnings per share basis. Atara Biotherapeutics employs 321 workers across the globe.View Additional Information About Atara Biotherapeutics.

What is Atara Biotherapeutics' official website?

The official website for Atara Biotherapeutics is http://www.atarabio.com/.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.

MarketBeat Community Rating for Atara Biotherapeutics (NASDAQ ATRA)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		379 (Vote Outperform)
Underperform Votes:		295 (Vote Underperform)
Total Votes:		674

MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe ATRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/19/2020 by MarketBeat.com Staff

Your Ultimate Investing Toolkit

Just $1.00 for your first month.